Molecular Epidemiology in the News
COPE Consortium aiding in COVID-19 crisis
The COronovirus Pandemic Epidemiology (COPE) Consortium now includes over 20 population-based cohort studies. Through COPE, we have developed an easy-to-use COVID-19 Symptom Study App to collect information on general health and whether individuals feel well or have symptoms. There are now over 3.8 million participants reporting symptoms in the US, UK, and Sweden. This offers an opportunity to rapidly introduce an easy-to-use data collection tool to track COVID-19 exposure, symptoms, and outcomes in real-time that will be invaluable for the current public health response as well as for your future studies. We welcome additional cohorts to join in our efforts. See our call to action in Cancer, Epidemiology, Biomarkers, and Prevention; our recent publications in Science and Nature Medicine; a recent NCI Cohort Consortium webinar; and media coverage in the New York Times.
Please contact us at [email protected] if you are interested and provide us details about your cohort, specific needs, and ideas about how this might complement work you are already planning or doing around COVID-19. Feel free to disseminate this to your colleagues.
Andy, Lorelei, Heather, and Walter
Andrew T. Chan, MD, Massachusetts General Hospital; Harvard T.H. Chan School of Public Health
Lorelei A. Mucci, MPH, ScD, Brigham and Women’s Hospital; Harvard T.H. Chan School of Public Health
A. Heather Eliassen, ScD, Harvard University, Channing Division of Network Medicine
Walter C. Willett, MD, Harvard T.H. Chan School of Public Health
Fifth International Molecular Pathological Epidemiology (MPE) Meeting, May 24-25, 2021, Dana-Farber Cancer Institute, Boston, Massachusetts
Drs. Shuji Ogino; Christine Ambrosone; Peter T. Campbell; Montserrat Garcia-Closas; and Timothy Rebbeck, Cochairs, cordially invite you to participate in this Meeting which is free-of-charge to all registrants. Keynote speakers are Drs. Todd Golub (Director, Cancer Program of Broad Institute) and Stephen Chanock (Director, Division of Cancer Epidemiology and Genetics, NCI, NIH). See the program; further details will be posted when confirmed. The registration site is open, with abstracts and poster sessions conducted as “retreat style.” To learn more, please visit the MPE Meeting website. For questions, please feel free to contact the meeting Cochairs or the meeting Secretary, Ms. Martina Bragg.
From the Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
The Epidemiology and Genomics Research Program in NCI’s Division of Cancer Control and Population Sciences invites AACR-MEG members to register for upcoming webinars. To learn more about the EGRP’s webinar series and to register for upcoming webinars, visit the SeqSPACE Upcoming Topics and Speakers webpage.
Be Sure to See the AACR Blog: Cancer Research Catalyst!
See current scientific research updates in the AACR’s blog Cancer Research Catalyst, and learn how you can submit content!
Request for Proposals for Genome-wide Investigation of Late-effects Using the Childhood Cancer Survivor Study (CCSS) Cohort
The Childhood Cancer Survivor Study (CCSS) is an NCI-funded resource for the study of long-term survivors of cancer diagnosed during childhood and adolescence. Learn the details regarding the cohort.
Members of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute and CCSS investigators collaborated to conduct a genome-wide association study, initially intended to study the role of genetic susceptibility in the development of subsequent neoplasms as well as first primary childhood cancers using samples from the CCSS Biorepository. Genotyping was conducted for 5739 childhood cancer survivors diagnosed 1970-1986 (5324 are of European ancestry) using the Illumina HumanOmni5Exome microarray, with over 4.1 million loci passing quality control thresholds (based on locus and sample missing rates, sample heterozygosity, and sex discrepancies).
The CCSS leadership is now broadening the scope of this initiative to study the role of genetic susceptibility in the development of non-malignant, treatment-related outcomes in cancer survivors. Accordingly, CCSS is announcing a request for proposals to collaborate with CCSS and NCI investigators in the use of existing genome-wide association study (GWAS) data and corresponding outcomes-related data to address innovative research questions relating to potential genetic contributions to risk for non-malignant treatment-related outcomes. Requests will be accepted on an ongoing basis and will be reviewed three times per year, in February, June, and October (cut-off for receipt of applications February 1, June 1, October 1).
Learn more details regarding the application process as well as the application for data access.
MEG Members Receive an Additional 5 Percent Discount on CEBP Accepted Manuscripts
MEG members receive a special 5 percent discount for publication fees only (not AuthorChoice) for articles accepted in Cancer Epidemiology, Biomarkers & Prevention (CEBP). This is in addition to the 5 percent discount given to all AACR members. Thus, MEG members receive a total discount of 10 percent. Just use the code “MEGAO2020” when receiving notification from the CEBP staff about author billing. See the information for authors for CEBP submissions. We look forward to receiving your submission.
CancerCareers Discounts Available
Be sure to check out cancercareers.org for career opportunities. MEG members receive a 15 percent discount for all employment postings. Use the code MEGAD when submitting your advertisement to receive this special rate. You can also sign-up for job alerts and refine a job search by a specific research area, i.e. epidemiology; prevention. Look on the right side of the website for these options.
To Submit an Announcement for Consideration, Please Note:
Postings of a non-employment nature may still be sent to [email protected] for review and possible future posting on the MEG Announcements.
Best regards from everyone at the AACR, and sincere appreciation for your